BRG1/BRM and prohibitin are required for growth suppression by estrogen antagonists
Estrogen antagonists are universally employed in the breast cancer therapy, although antagonist therapy is limited by the inevitable development of cellular resistance. The molecular mechanisms by which these agents inhibit cellular proliferation in breast cancer cells are not fully defined. Recent...
Сохранить в:
| Опубликовано в:: | EMBO J |
|---|---|
| Главные авторы: | , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Nature Publishing Group
2004
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC419909/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/15141164/ https://ncbi.nlm.nih.govhttps://doi.org/10.1038/sj.emboj.7600231 |
| Метки: |
Нет меток, Требуется 1-ая метка записи!
|